In the ACC subgroup, anlotinib significantly prolonged OS in patients with an EGFR mutation, an ECOG PS of 1, and >3 metastases and in patients who received two chemotherapy regimens and targeted regimens. Here, EGFR is linked to adrenal cortex carcinoma.